Compile Data Set for Download or QSAR
Report error Found 20 Enz. Inhib. hit(s) with all data for entry = 10860
TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575199(US11459333, Compound 131 | methyl (2S,4R)-4- (2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575202(US11459333, Compound 134 | isopropyl (2S,4R)- 4-(2...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575201(US11459333, Compound 133)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575201(US11459333, Compound 133)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575201(US11459333, Compound 133)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575201(US11459333, Compound 133)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575200(US11459333, Compound 132 | methyl (2S,4R)- 4-(2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575200(US11459333, Compound 132 | methyl (2S,4R)- 4-(2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575200(US11459333, Compound 132 | methyl (2S,4R)- 4-(2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575200(US11459333, Compound 132 | methyl (2S,4R)- 4-(2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575199(US11459333, Compound 131 | methyl (2S,4R)-4- (2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575199(US11459333, Compound 131 | methyl (2S,4R)-4- (2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575199(US11459333, Compound 131 | methyl (2S,4R)-4- (2-(4...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575202(US11459333, Compound 134 | isopropyl (2S,4R)- 4-(2...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575202(US11459333, Compound 134 | isopropyl (2S,4R)- 4-(2...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575202(US11459333, Compound 134 | isopropyl (2S,4R)- 4-(2...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575203(US11459333, Compound 135 | (2S,4R)-4-(2-(4- ((7-((...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575203(US11459333, Compound 135 | (2S,4R)-4-(2-(4- ((7-((...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575203(US11459333, Compound 135 | (2S,4R)-4-(2-(4- ((7-((...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM575203(US11459333, Compound 135 | (2S,4R)-4-(2-(4- ((7-((...)
Affinity DataIC50: 550nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
Go to US Patent